Atherosclerotic cardiovascular disease (ASCVD) broadly covers coronary artery disease, including acute coronary syndrome, a history of myocardial infarction, stable or unstable angina, as well as cerebrovascular disease and peripheral arterial disease. Drug treatment is individualized for the diagnosis but generally involves lipid-modifying, antihypertensive, and antithrombotic therapies. Despite the heavy entrenchment of generics, branded options of note include the lipid-modifying agents Repatha, Praluent, and Vascepa, and the oral antithrombotics Brilinta and Xarelto. This report demonstrates how ASCVD is pharmacologically managed for newly diagnosed and recently treated patients in the United States.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.
Markets covered: United States
Key companies: AstraZeneca, Janssen, Boehringer Ingelheim, Eli Lilly, Sanofi, Amgen, Amarin, Novo Nordisk.
Key drugs: Praluent, Repatha, Vascepa, Brilinta, Xarelto, clopidogrel, ezetimibe, SGLT-2 inhibitors, GLP-1 receptor agonists, ACE inhibitors, ARBs, beta blockers, CCBs, statins, fibrates, omega-3 acid ethyl esters.